GlobeNewswire·Nov 9, 2026, 7:30 AM ET

Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors

IMRX

Immuneering Corporation appointed Grant Bogle to its Board of Directors effective November 09, 2026.
Bogle brings over four decades of pharmaceutical \& biotechnology industry experience, specializing in oncology commercialization, sales, marketing, market access, \& corporate strategy.
Most recently, Bogle served on the Nuvalent board of directors prior to the company's 2026 acquisition by GlaxoSmithKline, focusing on commercial launch planning.
He previously acted as President \& CEO of Epizyme, Inc., where he led a corporate restructuring that facilitated the company's 2022 acquisition by Ipsen.
As Senior Vice President \& Chief Commercial Officer at TESARO, Inc., Bogle built U.S. commercial infrastructure \& led the launch of ZEJULA for ovarian cancer, contributing to the firm's 2019 acquisition by GlaxoSmithKline.
Earlier in his career, Bogle held senior leadership roles at Millennium Pharmaceuticals \& McKesson Specialty Health, including leading early U.S. commercialization for VELCADE.
Bogle highlighted Immuneering's atebimetinib data showing a 17.3-month median overall survival in first-line pancreatic cancer as unprecedented for the pathway.
He noted atebimetinib's potential to work across various RAS mutations \& its quality-of-life advantages regarding tolerability \& weight stability.
Bogle holds a BA in Economics from Dartmouth College \& an MBA from Columbia Business School.
Immuneering is developing Deep Cyclic Inhibitors, with its lead candidate atebimetinib currently in the global pivotal MAPKeeper 301 trial for first-line pancreatic cancer.

Company: Immuneering Corporation
Keywords: Nasdaq:IMRX, Immuneering Corporation, Immuneering, IMRX, atebimetinib, Atebi, PDAC, Pancreatic cancer, Commercial Leader, board of directors